CAU
PCRX icon

Caxton Associates (UK)’s Pacira BioSciences PCRX Stock Holding History

Caxton Associates (UK)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
56,917
+21,604
+61% +$511K 0.03% 335
2026
Q1 		$798K Sell
35,313
-14,683
-29% -$326K 0.02% 424
2025
Q4 		$1.29M Buy
49,996
+4,515
+10% +$107K 0.03% 299
2025
Q3 		$1.17M Sell
45,481
-2,026
-4% -$49.8K 0.03% 304
2025
Q2 		$1.14M Sell
47,507
-4,257
-8% -$107K 0.03% 294
2025
Q1 		$1.29M Buy
+51,764
New +$1.24M 0.04% 273

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caxton Associates (UK)'s PCRX Position: Q2 2026 in Review

Caxton Associates (UK) increased its Pacira BioSciences (PCRX) stake by 61% in Q2 2026, buying an estimated $511K and bringing the position to 56,917 shares worth $1.44M. The position accounts for 0.03% of the portfolio, ranked #335.

Caxton Associates (UK) first reported a position in PCRX in Q1 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Caxton Associates (UK) held 56,917 shares of Pacira BioSciences worth $1.44M as of Q2 2026.
  • Caxton Associates (UK) bought 21,604 Pacira BioSciences shares in Q2 2026, an estimated $511K.
  • Pacira BioSciences made up 0.03% of Caxton Associates (UK)'s portfolio in Q2 2026, its #335 holding.
  • Caxton Associates (UK) first reported a position in Pacira BioSciences in Q1 2025 and has held it in 6 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.